Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Protagonist Therapeutics (PTGX) reported a Q3 loss of $0.54 per share, which was better than the Zacks Consensus Estimate of a $0.59 loss. This is an improvement from the $0.58 loss per share reported a year ago.
November 07, 2024 | 11:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protagonist Therapeutics reported a Q3 loss of $0.54 per share, beating the expected loss of $0.59 per share. This is an improvement from the previous year's loss of $0.58 per share.
The better-than-expected earnings report, with a smaller loss than anticipated, is likely to have a positive short-term impact on PTGX's stock price. The improvement from last year's loss also suggests positive momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100